688 articles in this topic
Updated phase II data show a 37-month median response duration for ASPS patients on atezolizumab, with fusion type predicting outcomes.
The ICARUS-LUNG01 trial sheds light on why some lung cancer patients respond to antibody-drug conjugates while others resist.
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Peter Attia breaks down why prostate cancer deaths are rising despite available screening tools and how modern diagnostics can fix this.
Pre-treatment gut microbiome signatures predicted cancer recurrence in 674 melanoma patients receiving immune checkpoint blockade, with AUC up to 0.94.
New research reveals how RBM39 protein enhances DNA repair in liver cancer cells, suggesting combination therapy targets.
New study reveals combination therapy targeting ATR and DNA-PKcs kinases dramatically improves radiation response in ATM-deficient prostate cancers.
Researchers discover how SIRT6 protein overcomes temozolomide resistance in deadly brain cancer by modifying histone lactylation patterns.
Researchers find that combining Ganoderma lucidum and Sanghuangporus vaninii extracts may fight colorectal cancer through vitamin D and Wnt pathways.
Study maps hepatitis B virus DNA integration sites in liver cancer, revealing distinct patterns that predict patient outcomes.
Study of 183 brain tumor samples reveals distinct telomere maintenance patterns that could guide personalized cancer therapy.
